scholarly journals Combination of Fresh Frozen Plasma and Cryosupernatant Plasma for Therapeutic Plasma Exchange in Thrombotic Thrombocytopenic Purpura: A Single Institution Experience

2019 ◽  
Vol 2019 ◽  
pp. 1-6
Author(s):  
Qiuyan Lin ◽  
Liping Fan ◽  
Haobo Huang ◽  
Feng Zeng ◽  
Danhui Fu ◽  
...  

Purpose. To evaluate the impact of a combination of fresh frozen plasma (FFP) and cryosupernatant plasma (CP) as a replacement fluid in therapeutic plasma exchange (TPE) on early therapeutic response and long-term survival of patients with thrombotic thrombocytopenic purpura (TTP). Materials and Methods. A total of 44 patients with suspected TTP were screened by Bentley and PLASMIC scores. Twenty-seven patients treated with TPE using the FFP and CP combination as the replacement fluid were enrolled and divided into two groups: 11 patients who received TPE with CP-dominant replacement fluid (FFP/CP<1) and 16 patients who received TPE with FFP-dominant replacement fluid (FFP/CP>1). Results. There were no significant differences in the demographic and clinicopathological characteristics between the two groups except for the international normalized ratio (INR). The number of TPE procedures was lower, and time to achieve complete response was shorter in the CP-dominant group than in the FFP-dominant group. There were no significant differences in overall survival between the two groups. Conclusion. The CP-dominant replacement fluid was superior to the FFP-dominant replacement fluid in early response to TPE in patients with TTP, but did not impact the patients’ overall survival.

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 272-272
Author(s):  
James Louie ◽  
Fouad Boctor ◽  
Jason Chiang ◽  
Zeeshan Anwar ◽  
Amanda Wittenberg ◽  
...  

Abstract Abstract 272 The treatment of Thrombotic Thrombocytopenic Purpura (TTP) with therapeutic plasma exchange (TPE) with Fresh Frozen Plasma (FFP) and/or Cryopoor Plasma (CPP) replacement is well established. This process adds plasma ADAMTS-13 activity and removes plasma ADAMTS-13 inhibitor. Limited data has indicated combination of 5% albumin in the first half of the procedure followed by FFP in the second half of the procedure is effective in treating TTP. Theoretical calculation of addition of exogenous ADAMTS-13 is still substantial because ADAMTS-13 infused initially is removed as the plasma exchange procedure progresses. A 50% reduction of FFP would decrease the number of donor exposures and transfusion reactions associated with human plasma. Further, plasma of limited supply, such as AB plasma, can be more effectively used. We report a retrospective comparison of TPE for TTP using all FFP versus 5% Albumin/FFP (AFFP) replacement fluid. One health system with two closely connected tertiary campuses with common Hematology/Oncology services and Transfusion Medicine services treated 17 idiopathic TTP patients (March/2009 – June/2012) with documented very low ADAMTS-13 levels (<10) and high inhibitor levels (≥0.4). All other thrombotic microangiopathies were excluded from this comparison. One campus treated 10 patients with FFP and the other campus treated 7 patients with AFFP. Daily one plasma volume TPE was performed until target platelet count was achieved and the patient was then tapered off TPE. For AFFP replacement, 50% of the replacement fluid was 5% albumin given in the first half of the procedure followed by FFP for the second half. Additional medical therapy was managed by the same Hematology/Oncology service. Table 1 shows that the FFP versus the AFFP groups at presentations are comparable. Table 2 indicated FFP versus AFFP treatment is comparable. For the FFP and AFFP groups respectively, mean number of total procedures: 16 vs. 14, length of time from first TPE to last TPE 19 vs. 22 days, Relapses 2 vs. 2, and deaths 1 vs. 0. Conclusion: The use of AFFP as replacement fluid for idiopathic TTP does not appear to be inferior to 100% FFP replacement. Length of treatment, rate of recovery, and relapse rate are comparable. There were more deaths in the FFP cohort but the low number of observations limits the significance. AFFP fluid replacement should be considered for TPE in idiopathic TTP. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 2359-2359
Author(s):  
Amna G Khattak ◽  
Mansoor Ul Haq ◽  
Fnu Kaweeta ◽  
Mehmet Kocak ◽  
Robert Bradley ◽  
...  

Abstract Introduction Thrombotic thrombocytopenic purpura (TTP) is a serious medical condition characterized by endothelial injury and the formation of small vessel platelet-rich thrombi. If untreated, TTP-HUS in adults typically follows a progressive course in which irreversible renal failure, progressive neurologic deterioration, cardiac ischemia, and death are common outcomes. The mainstay of treatment for most patients with TTP is plasma exchange. Compared to the mortality rate of 90 percent prior to the use of plasma exchange, the mortality rate for patients treated with plasma exchange is 25 percent or less. Retrospective evidence shows no difference in outcomes based upon difference in composition of plasma exchange fluids. Based upon our observation, we hypothesized that patients treated with replacement fluid containing less than 100 percent fresh frozen plasma will have inferior outcomes in terms of achieving remission with frequent exacerbation, relapse and TTP related death. Method We conducted a retrospective chart review of 98 patients diagnosed and treated for first episode of TTP with plasma exchange at a tertiary referral center between 2004 and 2011. We recorded various patient and disease characteristics including gender, race, BMI, blood group, ADAMTS levels and any identifiable etiologies for secondary TTP. Based upon the composition of plasma replacement fluid, we divided to cohort into three groups; 100 percent fresh frozen plasma (FFP), Plasma with 50 % albumin and lastly a group which received both types of replacement fluids. We looked at the relationship of study outcomes; rate of remission, exacerbation, relapse and TTP related death with various patient and disease characteristics. We also compared the outcomes; rate of remission, exacerbation, relapse and TTP related death between the three types of plasma exchange groups in our cohort. Result The vast majority of our cohort comprised on African Americans (N= 84) females (N=64). Median age of the cohort was ---. Forty four patients were defined as having Idiopathic TTP where as secondary causes associated with TTP where identified in 53 patients. Forty eight patients received 100 % FFP, 23 received FFP in combination with 50 % albumin and 27 received both type of replacement fluids during plasma exchange. There was no statistically significant difference in the rate of remission, exacerbation, relapse and TTP related death based on gender, race, obesity, etiology and type of blood group. Patients with lower ADAMTS 13 level had higher likelihood of relapse (30.2% versus 8.3% p = 0.017). Patient achieved remission at a median duration of 40, 38 and 40 days in the 100 % plasma, 50/50 albumin and the combination groups respectively. There was no statistically significant difference in the rate of remission, exacerbation, relapse and TTP related death in the three treatment groups. Conclusion Amongst various patient and disease characteristics, only a low ADAMTS 13 level was significantly associated with increased rate of relapse. The median duration to remission was similar in the three plasma exchange groups irrespective of the type of replacement fluid. The type of replacement fluid used during plasma exchange has no impact on the rate of remission, exacerbation, relapse and TTP related death. However, a randomized prospective study is warranted to definitely answer this question. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 24-24
Author(s):  
Catherine A Klapheke ◽  
Chelsea Milito ◽  
Hannah L McRae ◽  
Neil Blumberg ◽  
Majed A Refaai

Background : Plasma exchange is the primary treatment for acute episodes of Thrombotic Thrombocytopenic Purpura (TTP), a rare condition characterized by the formation of thromboses in small blood vessels, resulting in thrombocytopenia, hemolytic anemia and multi-organ failure. Plasma exchange replacement fluids in TTP include Fresh Frozen Plasma (FFP) and solvent/detergent treated pooled plasma (SDP), such as Octaplas. SDP is a virus-inactivated, pooled human plasma product with standardized plasma protein content, including ADAMTS13, that has been used in the treatment of TTP. This study evaluates the effectiveness of SDP as compared to FFP in the treatment of acute TTP episodes. Study Design and Methods : A retrospective analysis was conducted comparing SDP- to FFP-treated patients with suspected acute TTP episodes as a primary admitting diagnosis between December 2014 and December 2019. A total of 16 patients were included in this study. The FFP group consisted of 9 patients (6M/3F, median age 44 years), three of whom had relapsed TTP. The SDP cohort had 7 patients (2M/5F, median age 38 years), one of whom had relapsed TTP. The primary outcomes measured included reported thromboembolic and major bleeding events. Secondary outcomes included number of plasma exchange procedures, adverse effects including neurological changes, transfusion of other blood products, ICU and hospital length of stay (LOS), and changes in laboratory values. Results : There were no adverse transfusion reactions reported in either group. 12 bleeding events were reported from 6 patients in the FFP group and 8 bleeding events from 4 patients in the SDP group (p=0.397). No significant differences were detected in ICU stay, hospital LOS, number of plasma units transfused, daily percentage of change of laboratory values, or changes in neurological status. Conclusions:These data confirm the previously reported efficacy of SDP for treating suspected/confirmed TTP.There were no significant differences in thromboembolic or bleeding events between patients who received FFP as compared to SDP. The non-significant differences observed in laboratory values throughout the duration of plasma exchange procedures as well as adverse reactions and clinical outcomes between both groups confirm the safety of SDP when used interchangeably with FFP for the treatment of TTP. Table Disclosures Blumberg: CSL Behring: Consultancy. Refaai:CSL Behring: Consultancy; Octapharma: Research Funding; Instrumentation Laboratory: Research Funding; iLine Microsystems: Research Funding; Diagnostica Stago: Consultancy.


Sign in / Sign up

Export Citation Format

Share Document